GLP-1 also slows down how quickly food leaves your stomach
Urinary Tract Infections: In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with empagliflozin compared to placebo (see Table 2)
We prescribe only branded, FDA-approved medications ensuring quality and reliability
These mechanisms support gradual weight reduction that aligns with metabolic function rather than short-term appetite control
Reach Your Weight Loss Goals with Wegovy Wegovy is a prescription weight loss medication containing semaglutide , a clinically proven GLP-1 receptor agonist
Food and Drug Administration (FDA) specifically for weight management.[1] In the STEP 1 clinical trial, Wegovy (2.4 mg) reduced body weight by 14.9% over 68 weeks in non-diabetic patients.[1] Wegovy is intended to be used alongside healthy eating and exercise in adults with obesity or who are overweight.[1] Individual semaglutide weight loss results may vary depending on lifestyle habits and other health factors